文献速递骨肌MR

膝关节腔内注射与膝骨关节炎进展:来自骨关节炎倡议的数据

Intra-articular Knee Injections and Progression of Knee Osteoarthritis: Data from the Osteoarthritis Initiative.
PubMed 文献 · Radiology · 2025-01-01

该研究基于骨关节炎倡议(OAI)多中心前瞻性纵向数据,分析210例接受关节腔内皮质类固醇或透明质酸注射者与倾向性评分匹配对照的2年MRI全关节半定量评估结果,发现皮质类固醇注射与较对照和透明质酸更明显的WORMS进展相关,而透明质酸注射与注射后2年内MRI进展减少相关,两者均与注射后疼痛减轻相关。

要点

  • 皮质类固醇注射者WORMS进展均值较对照高0.39(95%CI 0.05,0.75;P=.02),较透明质酸高0.42(95%CI 0.01,0.84;P=.04)。
  • 透明质酸注射者WORMS进展较注射同时期减少,均值差-0.42(95%CI -1.34,-0.28;P=.003)。
  • 皮质类固醇与透明质酸注射均与注射后WOMAC疼痛评分降低相关,均值差分别为-5.20(95%CI -6.91,-3.48;P=.001)和-2.15(95%CI -4.42,-0.13;P=.04)。

核心结论

  • 皮质类固醇注射与较透明质酸注射和对照更高的骨关节炎进展相关,而透明质酸与注射后2年内MRI进展减少相关。

研究设计与样本

  • 基于骨关节炎倡议(OAI)多中心纵向前瞻性研究的二次分析,纳入210例受试者(平均年龄64岁±7.9岁[SD],女性126例),比较接受皮质类固醇或透明质酸注射者与按年龄、性别、体重指数及临床变量倾向性评分匹配的对照,使用3-T MRI在注射时、2年前和2年后进行全器官MRI评分(WORMS)半定量分级。

关键影像表现/征象

  • 采用WORMS系统对软骨、骨髓病变和半月板进行半定量分级,评估注射后2年随访与注射时WORMS差值以量化进展。

诊断标准与关键数值

  • 皮质类固醇注射者WORMS进展均值较对照高0.39(95%CI 0.05,0.75;P=.02),较透明质酸注射者高0.42(95%CI 0.01,0.84;P=.04)。
  • 透明质酸注射者WORMS进展较注射同时期减少,均值差-0.42(95%CI -1.34,-0.28;P=.003)。
  • 皮质类固醇注射者WOMAC评分均值差-5.20(95%CI -6.91,-3.48;P=.001),透明质酸注射者WOMAC评分均值差-2.15(95%CI -4.42,-0.13;P=.04),均与注射后疼痛减轻相关。

临床应用与阅片要点

  • 在评估膝骨关节炎患者关节腔内注射史时,皮质类固醇注射者随访MRI可能显示更明显的WORMS进展,透明质酸注射者进展相对较少。
  • 解读注射后疼痛缓解时,皮质类固醇与透明质酸均与WOMAC疼痛评分降低相关,但需结合MRI进展评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background At least 10% of all patients with knee osteoarthritis (OA) undergo treatment with injectable corticosteroids or hyaluronic acid (HA). Although both have been shown to help with symptomatic pain relief, their long-term effects on knee OA progression remain inconclusive. Purpose To investigate the association between intra-articular knee injections, specifically corticosteroids and HA, and OA progression using a detailed whole-joint semiquantitative MRI evaluation and clinical outcomes for a period of 2 years. Materials and Methods This secondary analysis uses data from the Osteoarthritis Initiative (OAI), a multicenter, longitudinal, prospective study (February 2004 to January 2015). Participants who received a reported injection of corticosteroid or HA and propensity-score-matched controls (on age, sex, body mass index [calculated as weight in kilograms divided by height in meters squared], and clinical variables) were analyzed. Using the Whole-Organ MRI Score (WORMS) system for cartilage, bone marrow lesions, and meniscus, 3-T MRI performed at the time of injection, 2 years prior, and 2 years after were semiquantitatively graded. Postinjection progression was quantified using WORMS difference between time of injection and the 2-year follow-up. Associations with injection type were analyzed using repeated measures of analysis of covariance. Results There were 210 participants analyzed (mean age, 64 years ± 7.9 years [SD]; 126 female participants). Corticosteroids were associated with greater WORMS progression compared with controls (mean difference, 0.39; 95% CI: 0.05, 0.75; P = .02) and HA (0.42; 95% CI: 0.01, 0.84; P = .04). HA was associated with decreased WORMS progression compared with the injection-concurrent time frame (mean difference, -0.42; 95% CI: -1.34, -0.28; P = .003). Both corticosteroids (mean difference in Western Ontario and McMaster Universities Osteoarthritis Index scores, -5.20; 95% CI: -6.91, -3.48; P = .001) and HA injections (-2.15; 95% CI: -4.42, -0.13; P = .04) were associated with reduced pain after injection. Conclusion Corticosteroid injections were associated with higher OA progression than HA injections and controls, whereas HA was associated with decreased progression at MRI for up to 2 years after injection. ClinicalTrials.gov Identifier: NCT00080171 © RSNA, 2025.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Bharadwaj UU, Lynch JA, Joseph GB, et al. Intra-articular Knee Injections and Progression of Knee Osteoarthritis: Data from the Osteoarthritis Initiative. Radiology. 2025. PMID: 40423542. doi:10.1148/radiol.233081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。